In the third quarter, ending December 31, 2021, biosimilars revenues were up 28% year over year for Biocon Biologics Ltd.
Biosimilars revenues grew by 28% year over year for Biocon Biologics Ltd in the third quarter, which ended December 31, 2021, and is up 32% quarter over quarter.
During the quarter, the insulin glargine biosimilar (Semglee) launched in the United States with Biocon’s partner Viatris. In July 2021, Semglee was approved as the first interchangeable biosimilar. The interchangeable designation means that Semglee can be substituted for the reference product (Lantus) automatically by pharmacists without physicians' permission
“Biocon Biologics achieved a key milestone with the commercialization of the world's first interchangeable biosimilar, our Insulin Glargine, in the US,” Kiran Mazumdar-Shaw, executive chair at Biocon said in a statement. “Approvals for several of our generics and biosimilars in global markets, and renewal of key long-term research service agreements at Syngene, position us for a strong close to this fiscal [year]."
In addition, Biocon noted that Semglee received preferred status in 2 national formularies: Prime Therapeutics and Express Scripts. It will also be offered through the Walgreens Prescription Savings Club.
Semglee, which launched in the United States in November 2021, is available in vial and prefilled pen presentations. Arun Chandavarkar, PhD, managing director of Biocon, noted that following the approval and launch of Semglee in the United States, and robust demand in the United States and globally, the company has initiated an investment to expand the insulin manufacturing facility in Malaysia.
In Canada, Biocon’s bevacizumab biosimilar received approval during the third quarter. According to the financial report, market share for biosimilar trastuzumab (Ogivri) in the United States and biosimilar pegfilgrastim (Fulphila) in the United States and key European Union countries remained steady.
Biosimilar trastuzumab is the leading biosimilar in several countries and has close to half the market share in Brazil, Indonesia, and Algeria.
“The development of our next wave of biosimilars continues to progress well, with some of them poised to enter the clinic this quarter,” according to the report.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.